| Agennix AG to Present at Close Brothers Seydler Small and Mid Cap Conference in Frankfurt on February 4 |
 |
|
Company also Announces Fiscal Year 2009 Reporting Date will be March 24, 2010
Martinsried/Munich (Germany), Princeton, NJ and Houston, TX, February 2, 2010 – Agennix AG (Frankfurt Stock Exchange: AGX) today announced that the Company will give a corporate presentation at the upcoming Close Brothers Seydler Bank AG Small and Mid Cap Conference. The presentation will be on Thursday, February 4, 2010 at the IHK Frankfurt (Boerse), Frankfurt am Main, Germany. The Company also announced that it will report its business results for fiscal year 2009 on Wednesday, March 24, 2010. Agennix will hold a conference call to discuss the results and provide a corporate update on that day. Details will be published in advance of the call. About Agennix Agennix AG is a publicly traded biopharmaceutical company that is developing novel therapies in areas of major unmet medical need to improve the length and quality of life of seriously ill patients. The Company’s most advanced program is talactoferrin, an oral targeted therapy that is in Phase 3 clinical trials in non-small cell lung cancer. Agennix also has recently reported positive results from a Phase 2 trial evaluating talactoferrin in severe sepsis. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix is a transatlantic company with sites in Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com. This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. For further information, please contact: Investor Relations & Corporate Communications Phone: +49 (0)89 8565 2693 This e-mail address is being protected from spambots. You need JavaScript enabled to view it
In the U.S.: Laurie Doyle Director, Investor Relations & Corporate Communications Phone: +1 609 524 5884 This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Additional media contacts for Europe: MC Services AG Phone: +49 (0) 89 210 228 0
Raimund Gabriel This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Hilda Juhasz This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Additional investor contact for Europe: Trout International LLC Lauren Williams, Vice President Phone: +44 207 936 9325 This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|